Emmanuel Papadakis
Stock Analyst
(n/a)
# 4,633
Out of 4,641 analysts
41
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $110.98 | +35.16% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $53.39 | +49.84% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $8.83 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $76.95 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $12.90 | -6.98% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $52.89 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $115.74 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $2.70 | +1,196.30% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $114.07 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $557.92 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $37.98 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $110.98
Upside: +35.16%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $53.39
Upside: +49.84%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $8.83
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $76.95
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $12.90
Upside: -6.98%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $52.89
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $115.74
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $2.70
Upside: +1,196.30%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $114.07
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $557.92
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $37.98
Upside: -